Liver failure in patients treated with chemotherapy for colorectal liver metastases: Role of chronic disease scores in patients undergoing major liver surgery. A case-matched analysis

Eur J Surg Oncol. 2014 Nov;40(11):1550-6. doi: 10.1016/j.ejso.2014.06.011. Epub 2014 Jul 18.

Abstract

Aim: An accurate and noninvasive tool to predict Chemotherapy Associated Liver Injury (CALI) still lacks. Study aimed to evaluate chronic liver disease scores (Aspartate aminotransferase to Platelet Ratio Index, APRI and Fibrosis-4, FIB-4) as Postoperative Liver Failure (PLF) predictors in patients treated with Oxaliplatin for Colorectal Liver Metastases (CLM).

Methods: 8 patients who developed PLF after major hepatectomy (Group B) were compared to 24 patients who did not develop PLF (Group A) in a case-matched analysis for patients and disease characteristics. ROC curves analysis was performed to assess score accuracy.

Results: In Group A number of CT cycles was lower, (6 vs 9, p NS), interval between treatment and surgery was longer (11 vs 7 weeks, p < 0.05) and bevacizumab was more frequently administered (66.7% vs 37.5%, p < 0.05). In Group B median APRI score was 0.53 (range: 0.86-4.26) whereas in Group A was 0.30 (range: 0.06-2.21, p < 0.05). Median FIB-4 score was 2.46 (range: 0.86-13.65) in Group B and 1.58 (range: 0.27-7.68) in Group A (p < 0.001). Multivariate analysis showed a significant correlation between APRI and the onset of PLF. A good accuracy of APRI score was evident in ROC curves with an area under the curve of 0.72 (p 0.003).

Conclusions: APRI score is calculated considering both liver damage and platelet count, it is cost effective and easily available. This study demonstrates that there is a good accuracy in PLF prediction and consequently in CT induced liver damage evaluation.

Keywords: Chemotherapy; Liver surgery; Metastases; Sinusoidal obstruction; postoperative liver failure.

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents / adverse effects*
  • Aspartate Aminotransferases / blood
  • Bevacizumab
  • Chemical and Drug Induced Liver Injury / blood
  • Chemical and Drug Induced Liver Injury / etiology*
  • Chronic Disease
  • Colorectal Neoplasms / pathology*
  • Female
  • Hepatectomy / adverse effects*
  • Humans
  • Liver Failure / etiology*
  • Liver Neoplasms / secondary
  • Liver Neoplasms / therapy*
  • Male
  • Matched-Pair Analysis
  • Middle Aged
  • Neoadjuvant Therapy*
  • Organoplatinum Compounds / adverse effects
  • Oxaliplatin
  • Platelet Count
  • ROC Curve
  • Retrospective Studies
  • Risk Factors

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Organoplatinum Compounds
  • Oxaliplatin
  • Bevacizumab
  • Aspartate Aminotransferases